Replies to post #237280 on Biotech Values

[DewDiligence]

FDA_briefing_doc_for PFE/LLY’s Tanezumab doesn’t_look_promising:

https://www.fda.gov/media/146867/download

The advisory panel meets all day Wednesday and Thursday morning.

The good news, such as it is, is that essentially nobody has any projected sales for this drug in valuation models.